Table 3 Univariate and multivariate analysis of risk factors for IFD
Risk factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Patient age (years) | ||||
< 50 versus ≥ 50 | 0.947 (0.307–2.920) | 0.925 | ||
Gender | ||||
Female versus male | 0.503 (0.166–1.529) | 0.226 | ||
Underlying disease, no. (%) | ||||
AML | 1.0 | |||
ALL | 0.737 (0.216–2.509) | 0.625 | ||
Othera | 0.367 (0.102–1.321) | 0.125 | ||
Stage of underlying disease | ||||
CR versus Non-CR | 0.611 (0.129–2.896) | 0.534 | ||
Diabetes | ||||
Yes versus no | 2.057(0.504–8.399) | 0.315 | ||
Transplant type | ||||
MSD vs HID | 0.543 (0.146–2.025) | 0.363 | ||
Conditioning regimen | ||||
Reduced intensity vs Myeloablative | 0.0 (0.0) | 0.998 | ||
GVHD prophylaxis | ||||
ATG-based vs no ATG-based | 0.851 (0.253–2.869) | 0.795 | ||
History of IFD pre-transplant | ||||
No versus yes | 0.537 (0.180–1.602) | 0.265 | ||
CMV DNA | ||||
Negative versus positive | 0.711 (0.245–2.067) | 0.531 | ||
CMV disease | ||||
Yes versus no | 14.306 (3.033–67.481) | 0.001 | 12.591(2.571–61.650) | 0.002 |
Acute GVHD | ||||
Grades III–IV versus Grades 0–II | 3.309 (1.064–10.393) | 0.039 | 2.770 (0.801–9.579) | 0.107 |
Chronic GVHD | ||||
Extensive versus no/limited | 1.678 (0.565–4.985) | 0.351 | ||